

## Anti-FGF21R Antibody (Efruxifermin)

### Introduction

Efruxifermin is a recombinant human fibroblast growth factor 21 (FGF21) analogue, mainly used to treat non-alcoholic steatohepatitis (NASH). Its mechanism is to activate the FGF21 signaling pathway, regulate metabolic processes, reduce liver fat accumulation and inflammatory response. Efruxifermin was developed by Akero Therapeutics, a US biotechnology company.

### Product parameters

Alternative Names	AKR-001
Target Accession	-
Target	FGF21R
CAS number	2375240-92-7
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

